News cancer patient samplesThis news is encouraging going forward!!I would expect MOM to improve in the Summer when resource is quieter!!
Dot
Miraculins to access cancer patient samples
Miraculins Inc (TSX-V:MOM)
Shares Issued 15,021,500
Last Close 2/21/2006 $1.33
Wednesday February 22 2006 - News Release
Dr. Jim Charlton reports
MIRACULINS ACCESSES ESSENTIAL SAMPLES THROUGH AGREEMENT WITH INTERNATIONAL
Miraculins Inc. has reached an agreement with the European Tumor Sample Institute gGmbH (ETSI-med) to access a population of samples key to Miraculins's research and development strategies.
The agreement with ETSI-med allows Miraculins to access clinical patient samples for colorectal, breast, gastric and pancreatic cancers, from one of Europe's most modern sample banks. Importantly, these samples were obtained from patients that were formerly part of the discovery work and intellectual property filings of Europroteome AG. Miraculins purchased the intellectual property assets of Europroteome AG in June of 2005, and with the acquisition gained a foothold in numerous cancer diagnostic areas.
"The markers we acquired from Europroteome are very exciting. Reliably reproducing their findings is the next important step in moving this work forward," stated Dr. Jim Charlton, president of Miraculins. "We are very pleased to be working with CEO Dr. Lueder Fels and his team at ETSI-med, and exercising the critical know-how we acquired as part of our purchase of Europroteome."
"Miraculins's research platform is ideally suited to detect cancer markers in clinical samples," stated Dr. Lueder Fels, chief executive officer of ETSI-med. "Biobanks can provide the foundation for significant breakthroughs in medical and pharmaceutical research by providing high-quality biological material for research, but it takes innovative companies like Miraculins to develop new tools for cancer diagnosis."
In addition to markers that support the company's breast cancer discovery project, the purchase of Europroteome saw Miraculins acquire discovery stage markers implicated in colorectal, gastric, pancreatic and numerous epithelial cancers.
About ETSI-med
ETSI-med is a non-profit organization founded with the goal of improving the prevention, diagnosis and therapy of cancer. The company's biobank comprises tissues and blood donated by several thousand cancer patients. Private and public institutions can attain access to anonymized, clinically annotated samples. Biological materials can also be collected selectively for specific customer projects.
ETSI-med has its roots in an academic network of cancer specialists established in Switzerland in the late 1990s. For research projects on gastrointestinal cancer, protocols were developed to collect samples of human biological material and the relevant donor health status information. Members of the network were actively involved in advancing the ethical principles and legal framework of biobanks at the national and international level.
From 2000 to 2004, the infrastructure necessary for the network and the continuing collection was supported by the biotech company Europroteome AG. In 2005 ETSI-med was founded as a non-profit organization with the purpose of expanding the collection and making it available to researchers worldwide.
© 2006 Canjex Publishing Ltd.